All Stories

Blueprint changes up $1.67B VantAI pact again, zeroing in on molecular glue potential

Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and prioritizing new target-effector pairs that could be used to develop molecular glue therapeutics.

May 20, 2025 - 16:10
 0
Blueprint changes up $1.67B VantAI pact again, zeroing in on molecular glue potential
Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and prioritizing new target-effector pairs that could be used to develop molecular glue therapeutics.
Read More

Tags:

Previous Article

All branded drugs not facing generic, biosimilar competition must abide by MFN o...

Next Article

SV Health’s latest pharma-backed dementia fund raises $269M to invest in new the...

Related Posts

Kinase inhibitor biotech Enliven calls time on ph. 1 HER2 solid tumor program

Kinase inhibitor biotech Enliven calls time on ph. 1 HE...

May 15, 2025  0

Makary outlines AI plans and the broader vision for his term as FDA commissioner

Makary outlines AI plans and the broader vision for his...

May 15, 2025  0

Stars align for CRISPR Tx, Sirius as pair pen siRNA collab with a focus on thrombotic disease

Stars align for CRISPR Tx, Sirius as pair pen siRNA col...

May 20, 2025  0